Literature DB >> 28630325

Convergent immunological solutions to Argentine hemorrhagic fever virus neutralization.

Antra Zeltina1, Stefanie A Krumm2, Mehmet Sahin3, Weston B Struwe4, Karl Harlos1, Jack H Nunberg5, Max Crispin4,6, Daniel D Pinschewer3, Katie J Doores7, Thomas A Bowden8.   

Abstract

Transmission of hemorrhagic fever New World arenaviruses from their rodent reservoirs to human populations poses substantial public health and economic dangers. These zoonotic events are enabled by the specific interaction between the New World arenaviral attachment glycoprotein, GP1, and cell surface human transferrin receptor (hTfR1). Here, we present the structural basis for how a mouse-derived neutralizing antibody (nAb), OD01, disrupts this interaction by targeting the receptor-binding surface of the GP1 glycoprotein from Junín virus (JUNV), a hemorrhagic fever arenavirus endemic in central Argentina. Comparison of our structure with that of a previously reported nAb complex (JUNV GP1-GD01) reveals largely overlapping epitopes but highly distinct antibody-binding modes. Despite differences in GP1 recognition, we find that both antibodies present a key tyrosine residue, albeit on different chains, that inserts into a central pocket on JUNV GP1 and effectively mimics the contacts made by the host TfR1. These data provide a molecular-level description of how antibodies derived from different germline origins arrive at equivalent immunological solutions to virus neutralization.

Entities:  

Keywords:  antibody response; arenavirus; glycoprotein; hemorrhagic fever; structure

Mesh:

Substances:

Year:  2017        PMID: 28630325      PMCID: PMC5502616          DOI: 10.1073/pnas.1702127114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  55 in total

1.  Emerging diseases. New arenavirus blamed for recent deaths in California.

Authors:  M Enserink
Journal:  Science       Date:  2000-08-11       Impact factor: 47.728

Review 2.  Exotic emerging viral diseases: progress and challenges.

Authors:  Thomas W Geisbert; Peter B Jahrling
Journal:  Nat Med       Date:  2004-12       Impact factor: 53.440

3.  Cross-neutralizing human anti-poliovirus antibodies bind the recognition site for cellular receptor.

Authors:  Zhaochun Chen; Elizabeth R Fischer; Diana Kouiavskaia; Bryan T Hansen; Steven J Ludtke; Bella Bidzhieva; Michelle Makiya; Liane Agulto; Robert H Purcell; Konstantin Chumakov
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-25       Impact factor: 11.205

4.  Structural families in loops of homologous proteins: automatic classification, modelling and application to antibodies.

Authors:  A C Martin; J M Thornton
Journal:  J Mol Biol       Date:  1996-11-15       Impact factor: 5.469

5.  Past, present, and future of arenavirus taxonomy.

Authors:  Sheli R Radoshitzky; Yīmíng Bào; Michael J Buchmeier; Rémi N Charrel; Anna N Clawson; Christopher S Clegg; Joseph L DeRisi; Sébastien Emonet; Jean-Paul Gonzalez; Jens H Kuhn; Igor S Lukashevich; Clarence J Peters; Victor Romanowski; Maria S Salvato; Mark D Stenglein; Juan Carlos de la Torre
Journal:  Arch Virol       Date:  2015-07       Impact factor: 2.574

6.  Viral receptor-binding site antibodies with diverse germline origins.

Authors:  Aaron G Schmidt; Matthew D Therkelsen; Shaun Stewart; Thomas B Kepler; Hua-Xin Liao; M Anthony Moody; Barton F Haynes; Stephen C Harrison
Journal:  Cell       Date:  2015-05-07       Impact factor: 41.582

7.  Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega.

Authors:  Fabian Sievers; Andreas Wilm; David Dineen; Toby J Gibson; Kevin Karplus; Weizhong Li; Rodrigo Lopez; Hamish McWilliam; Michael Remmert; Johannes Söding; Julie D Thompson; Desmond G Higgins
Journal:  Mol Syst Biol       Date:  2011-10-11       Impact factor: 11.429

8.  Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits.

Authors:  James E Robinson; Kathryn M Hastie; Robert W Cross; Rachael E Yenni; Deborah H Elliott; Julie A Rouelle; Chandrika B Kannadka; Ashley A Smira; Courtney E Garry; Benjamin T Bradley; Haini Yu; Jeffrey G Shaffer; Matt L Boisen; Jessica N Hartnett; Michelle A Zandonatti; Megan M Rowland; Megan L Heinrich; Luis Martínez-Sobrido; Benson Cheng; Juan C de la Torre; Kristian G Andersen; Augustine Goba; Mambu Momoh; Mohamed Fullah; Michael Gbakie; Lansana Kanneh; Veronica J Koroma; Richard Fonnie; Simbirie C Jalloh; Brima Kargbo; Mohamed A Vandi; Momoh Gbetuwa; Odia Ikponmwosa; Danny A Asogun; Peter O Okokhere; Onikepe A Follarin; John S Schieffelin; Kelly R Pitts; Joan B Geisbert; Peter C Kulakoski; Russell B Wilson; Christian T Happi; Pardis C Sabeti; Sahr M Gevao; S Humarr Khan; Donald S Grant; Thomas W Geisbert; Erica Ollmann Saphire; Luis M Branco; Robert F Garry
Journal:  Nat Commun       Date:  2016-05-10       Impact factor: 14.919

9.  Host-species transferrin receptor 1 orthologs are cellular receptors for nonpathogenic new world clade B arenaviruses.

Authors:  Jonathan Abraham; Jo Ann Kwong; César G Albariño; Jiajie G Lu; Sheli R Radoshitzky; Jorge Salazar-Bravo; Michael Farzan; Christina F Spiropoulou; Hyeryun Choe
Journal:  PLoS Pathog       Date:  2009-04-03       Impact factor: 6.823

10.  Unusual molecular architecture of the machupo virus attachment glycoprotein.

Authors:  Thomas A Bowden; Max Crispin; Stephen C Graham; David J Harvey; Jonathan M Grimes; E Yvonne Jones; David I Stuart
Journal:  J Virol       Date:  2009-06-03       Impact factor: 5.103

View more
  21 in total

Review 1.  Crossing the Iron Gate: Why and How Transferrin Receptors Mediate Viral Entry.

Authors:  Marianne Wessling-Resnick
Journal:  Annu Rev Nutr       Date:  2018-05-31       Impact factor: 11.848

2.  A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins.

Authors:  Xavier Carnec; Mathieu Mateo; Audrey Page; Stéphanie Reynard; Jimmy Hortion; Caroline Picard; Elsie Yekwa; Laura Barrot; Stéphane Barron; Audrey Vallve; Hervé Raoul; Caroline Carbonnelle; François Ferron; Sylvain Baize
Journal:  J Virol       Date:  2018-05-29       Impact factor: 5.103

3.  Monoclonal Antibodies with Neutralizing Activity and Fc-Effector Functions against the Machupo Virus Glycoprotein.

Authors:  Fatima Amanat; James Duehr; Cheng Huang; Slobodan Paessler; Gene S Tan; Florian Krammer
Journal:  J Virol       Date:  2020-02-14       Impact factor: 5.103

4.  TFRC upregulation promotes ferroptosis in CVB3 infection via nucleus recruitment of Sp1.

Authors:  Lu Yi; Yanan Hu; Zhixiang Wu; Ying Li; Min Kong; Zhijuan Kang; Bojiao Zuoyuan; Zuocheng Yang
Journal:  Cell Death Dis       Date:  2022-07-11       Impact factor: 9.685

5.  Machupo Virus with Mutations in the Transmembrane Domain and Glycosylation Sites of the Glycoprotein Is Attenuated and Immunogenic in Animal Models of Bolivian Hemorrhagic Fever.

Authors:  Emily K Mantlo; Junki Maruyama; John T Manning; Timothy G Wanninger; Cheng Huang; Jeanon N Smith; Michael Patterson; Slobodan Paessler; Takaaki Koma
Journal:  J Virol       Date:  2022-03-28       Impact factor: 6.549

6.  Bivalent Junin & Machupo experimental vaccine based on alphavirus RNA replicon vector.

Authors:  Dylan M Johnson; Jenny D Jokinen; Min Wang; Tia Pfeffer; Irina Tretyakova; Ricardo Carrion; Anthony Griffiths; Peter Pushko; Igor S Lukashevich
Journal:  Vaccine       Date:  2020-02-25       Impact factor: 3.641

7.  Second-Generation Live-Attenuated Candid#1 Vaccine Virus Resists Reversion and Protects against Lethal Junín Virus Infection in Guinea Pigs.

Authors:  Brady T Hickerson; Joanne York; Jonna B Westover; Brian B Gowen; Eric J Sefing; Kevin W Bailey; Luci Wandersee; Jack H Nunberg
Journal:  J Virol       Date:  2021-06-24       Impact factor: 5.103

8.  Structural analysis of glycoproteins: building N-linked glycans with Coot.

Authors:  Paul Emsley; Max Crispin
Journal:  Acta Crystallogr D Struct Biol       Date:  2018-04-06       Impact factor: 7.652

9.  Structure of the Lassa virus glycan shield provides a model for immunological resistance.

Authors:  Yasunori Watanabe; Jayna Raghwani; Joel D Allen; Gemma E Seabright; Sai Li; Felipe Moser; Juha T Huiskonen; Thomas Strecker; Thomas A Bowden; Max Crispin
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-25       Impact factor: 11.205

10.  Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses.

Authors:  Lars E Clark; Selma Mahmutovic; Donald D Raymond; Taleen Dilanyan; Takaaki Koma; John T Manning; Sundaresh Shankar; Silvana C Levis; Ana M Briggiler; Delia A Enria; Kai W Wucherpfennig; Slobodan Paessler; Jonathan Abraham
Journal:  Nat Commun       Date:  2018-05-14       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.